Senior Management Team




  • linkedin

Dr Gillian Broadbent is a molecular biologist with over 20 years’ experience in the field of protein engineering. She was previously a co-founder and Director of Research and Development for Haptogen Ltd until its sale to Wyeth in October 2007. During her time at Haptogen she was involved in developing human therapeutic antibodies to hapten targets that are difficult to address with conventional antibody generation approaches. She has considerable expertise in the development of recombinant antibodies from a number of sources and in their development for both diagnostic and therapeutic applications. In 2012, she co-founded Scotia Biologics Ltd., where she acts as COO/CFO.


During her time in industry, Dr Broadbent has been involved in the project management of a large number of contracts with external clients as well as internal R&D ensuring that projects were completed on time and materials produced met the specific requirements of the clients. Gillian also has experience of managing collaborations involving companies from all over the world, the longest being an 8 year collaboration with a Malaysian company.



  • linkedin

Dr. Keith Charlton obtained his Ph.D. from the University of Aberdeen in 2000, and is a molecular immunologist with over 20 years experience. His main research interest is in the field of antibody engineering, particularly the application of cutting edge technologies to generate high affinity recombinant antibodies from novel sources to challenging antigens, and developing these into commercially successful diagnostic, therapeutic and research reagents. His work has been widely published in the scientific press and presented at numerous international meetings. In 2002 he was one of the scientific founders and director of innovations of Haptogen Ltd., a University of Aberdeen spin-out biotechnology company specializing in generating therapeutic antibodies to antigens not easily targeted effectively by conventional antibody technologies. Haptogen was successfully acquired by Wyeth Pharmaceuticals in late 2007. In 2012 he co-founded Scotia Biologics Ltd., where he acts as CEO/CSO.


Principal Scientist


  • linkedin

Dr Euan Murray joined Scotia at the start of 2016.  His role as Principal Scientist involves coordinating a number of customers’ projects as well as much of our internal R&D.  When in the lab he is likely to be found building or screening antibody-phage libraries.

Prior to joining Scotia he spent 11 years at The Cancer Research UK Edinburgh Centre in the lab of Ted Hupp. Here he was involved in many interesting and varied molecular oncology projects, covering areas such as cell signaling, proteomics and antibody engineering.  It was during this time that he learned how to carry out phage display; skills now being put to good use at Scotia.

Euan has a BSc in Biology & Chemistry from Abertay University, Dundee and a PhD in Bioorganic Chemistry from Heriot Watt University, Edinburgh.


Laboratory & Quality Manager


  • linkedin

Dr Jennifer Middleton received her B.Sc. (Hons) in Molecular Microbiology, and her PhD. in Microbiology from the University of Aberdeen.  Following her postgraduate studies, she worked on building antibody libraries as a Senior Research Scientist at Haptogen Ltd., which was subsequently acquired by Wyeth then Pfizer.  In 2012 she joined Scotia Biologics Ltd. as a Senior Research Scientist developing cancer vaccines based on growth factors proteins.  


In 2018 she was promoted to Quality & Laboratory Manager, where she manages Scotia’s ISO9001:2015 standard.